KALA BIO, Inc. (KALA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Arlington, MA, アメリカ. 現CEOは Avi Minkowitz.
KALA を有する IPO日 2017-07-20, 38 名の正社員, に上場 NASDAQ Global Select, 時価総額 $4.2M.
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
